Permira Seeks Sale of Cambrex at $4 Billion Valuation, FT Says

Private equity group Permira plans to sell US-based drugmaker Cambrex Corp. and seeks a valuation of as much as $4 billion for the business, the Financial Times reports, citing people familiar with the matter.

Permira has hired advisers to launch the sale, with the auction process focused on private equity buyers, according to the report. There is no guarantee that a transaction will take place, the newspaper notes.

Permira and Cambrex didn’t immediately respond to the FT’s request for comment.

Cambrex is a contract development and manufacturing organization for the pharmaceutical industry. It was acquired by Permira in 2019 ...